



## FASN-IN-1

<b>Cat. No.:</b>	OB0225LY-0028
<b>Appearance:</b>	Solid
<b>Purity:</b>	≥99%
<b>Identity:</b>	Confirmed by NMR.
<b>Size:</b>	1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg; 500 mg


This product is for research use only and is not intended for diagnostic use.

### Product Overview

<b>Description</b>	FASN-IN-1 is a small molecule compound that inhibits fatty acid synthase (FASN) and reduces fatty acid synthesis, thereby affecting cellular energy metabolism.
<b>Synonym</b>	TVB-2460; 1808260-84-5; (2S)-N-[4-[4-(Diethylsulfamoyl)phenyl]-1,3-thiazol-2-yl]-2-methylbutanamide
<b>CAS No.</b>	1808260-84-5
<b>Compound CID</b>	118356203
<b>Formula</b>	C <sub>18</sub> H <sub>25</sub> N <sub>3</sub> O <sub>3</sub> S <sub>2</sub>
<b>Formula Weight</b>	395.54

### Specification

<b>Relative Density</b>	1.240 g/cm <sup>3</sup>
<b>IUPAC Name</b>	(2S)-N-[4-[4-(Diethylsulfamoyl)phenyl]-1,3-thiazol-2-yl]-2-methylbutanamide
<b>InChI</b>	InChI=1S/C18H25N3O3S2/c1-5-13(4)17(22)20-18-19-16(12-25-18)14-8-10-15(11-9-14)26(23,24)21(6-2)7-3/h8-13H,5-7H2,1-4H3,(H,19,20,22)/t13-/m0/s1
<b>InChI Key</b>	IXMQVFSSASHOGM-ZDUSSCGKSA-N
<b>SMILES string</b>	CC[C@H](C)C(=O)NC1=NC(=CS1)C2=CC=C(C=C2)S(=O)(=O)N(CC)CC
<b>Stability</b>	3 years in powder form.
<b>Storage</b>	Storage at -20°C.

**Applications**

FASN-IN-1 is mainly used in obesity-related cancer research, especially in certain cancer cell types that depend on fatty acid synthesis. Its inhibitory effects may also be important in the treatment of metabolic syndrome and obesity-related diseases.

**Library Information**

<b>Targets</b>	Fatty acid synthase
<b>Receptors</b>	Fatty acid synthase
<b>Pathways</b>	Metabolism
<b>Plate Number</b>	AOCL-1
<b>Plate Location</b>	c9
<b>Empty Location</b>	a1-h1; a12-h12
<b>Container</b>	96-well plate
<b>Formulation</b>	10 mM DMSO
<b>DMSO Max Solubility</b>	100 mg/mL; 252.82 mM